洛拉替尼对比克唑替尼治疗晚期ALK阳性非小细胞肺癌:III期CROWN研究5年结局
III期CROWN研究5年随访显示,洛拉替尼对比克唑替尼一线治疗晚期ALK阳性非小细胞肺癌,中位无进展生存期洛拉替尼组未达到,克唑替尼组9.1个月(HR 0.19);5年无进展生存率分别为60%和8%,颅内进展中位时间洛拉替尼组未达到,克唑替尼组16.4个月(HR 0.06)。
要点
- 洛拉替尼组中位无进展生存期未达到,克唑替尼组为9.1个月(HR 0.19)。
- 5年无进展生存率洛拉替尼组60%,克唑替尼组8%。
- 颅内进展中位时间洛拉替尼组未达到,克唑替尼组16.4个月(HR 0.06)。
核心结论
- 5年随访后洛拉替尼组中位无进展生存期仍未达到,为晚期非小细胞肺癌及所有转移性实体瘤中单药分子靶向治疗报告的最长无进展生存期。
- 这些结果结合持久的颅内疗效和未出现新的安全性信号,为晚期ALK阳性非小细胞肺癌患者带来了前所未有的结局,并设立了癌症靶向治疗的新基准。
研究设计与样本
- III期CROWN研究的事后分析,296例既往未治疗的晚期ALK阳性非小细胞肺癌患者按1:1随机分配接受洛拉替尼100 mg每日一次(n=149)或克唑替尼250 mg每日两次(n=147)。
- 本次报告更新研究者评估的疗效、安全性和生物标志物分析结果。
主要发现
- 无进展生存期中位随访时间洛拉替尼组60.2个月、克唑替尼组55.1个月;中位无进展生存期洛拉替尼组未达到(NR,95%CI 64.3至NR),克唑替尼组9.1个月(95%CI 7.4至10.9),HR 0.19(95%CI 0.13至0.27)。
- 5年无进展生存率洛拉替尼组60%(95%CI 51至68),克唑替尼组8%(95%CI 3至14)。
- 颅内进展中位时间洛拉替尼组未达到(95%CI NR至NR),克唑替尼组16.4个月(95%CI 12.7至21.9),HR 0.06(95%CI 0.03至0.12)。
- 安全性特征与既往分析一致。
- 洛拉替尼治疗结束时采集的循环肿瘤DNA中未检测到新出现的ALK耐药突变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lorlatinib improved progression-free survival (PFS) and intracranial activity versus crizotinib in patients with previously untreated, advanced, ALK-positive non-small cell lung cancer (NSCLC) in the phase III CROWN study. Here, we report long-term outcomes from CROWN after 5 years of follow-up. METHODS: Two hundred ninety-six patients with ALK-positive NSCLC were randomly assigned 1:1 to receive lorlatinib 100 mg once daily (n = 149) or crizotinib 250 mg twice daily (n = 147). This post hoc analysis presents updated investigator-assessed efficacy outcomes, safety, and biomarker analyses. RESULTS: With a median follow-up for PFS of 60.2 and 55.1 months, respectively, median PFS was not reached (NR [95% CI, 64.3 to NR]) with lorlatinib and 9.1 months (95% CI, 7.4 to 10.9) with crizotinib (hazard ratio [HR], 0.19 [95% CI, 0.13 to 0.27]); 5-year PFS was 60% (95% CI, 51 to 68) and 8% (95% CI, 3 to 14), respectively. Median time to intracranial progression was NR (95% CI, NR to NR) with lorlatinib and 16.4 months (95% CI, 12.7 to 21.9) with crizotinib (HR, 0.06 [95% CI, 0.03 to 0.12]). Safety profile was consistent with that in prior analyses. Emerging new ALK resistance mutations were not detected in circulating tumor DNA collected at the end of lorlatinib treatment. CONCLUSION: After 5 years of follow-up, median PFS has yet to be reached in the lorlatinib group, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumors. These results coupled with prolonged intracranial efficacy and absence of new safety signals represent an unprecedented outcome for patients with advanced ALK-positive NSCLC and set a new benchmark for targeted therapies in cancer.
引用
- Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024. PMID: 38819031. doi:10.1200/JCO.24.00581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。